Evidence map›Paper›PMID 40500529›Full record

GuidelineEuropean radiology2025

ESR Essentials: diagnosis and assessment of treatment response in patients with luminal Crohn's disease-practice recommendations by the European Society of Gastrointestinal and Abdominal Radiology.

Maira Hameed, Isabelle De Kock, Jaap Stoker, Stuart A Taylor

Abstract readPractice GuidelineReview
In one paragraph

Guideline in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. [Imaging diagnostics for diseases of the small bowel].Radiologie (Heidelberg, Germany) · 2026
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maira Hameed *Department of Radiology, University College London Hospitals, London, UK.
Isabelle De Kock *Department of Radiology, Ghent University Hospital, Ghent, Belgium.
Jaap StokerDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Stuart A TaylorDepartment of Radiology, University College London Hospitals, London, UK. stuart.taylor@ucl.ac.uk.ORCID http://orcid.org/0000-0002-6765-8806

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) presents an ESR Essentials review article on Crohn's disease (CD) diagnosis and treatment response assessment. The focus is on luminal disease, particularly in the small bowel, and to a lesser degree, the colon. Magnetic Resonance Enterography (MRE) and ultrasound are typically the first-line radiological investigations for known or suspected luminal CD. They are accurate for assessing the entirety of the bowel wall and extra-enteric tissues and are generally well tolerated by patients. CT has utility as well, especially in the acute setting. Disease location, extent, and phenotype should be assessed. Well-validated imaging signs of acute inflammation (active disease) are responsive to therapeutic interventions and include bowel mural thickening and oedema, perimural inflammation, ulceration, and hypervascularity. Other phenotypes (stricturing or penetrating with fistulae and/or abscesses) can coexist, and the predominant disease phenotype should be established. We recommend that radiologists work closely within multidisciplinary teams to optimise imaging selection for individual patients, tailored to the clinical question. Findings should be clearly communicated to best inform management decisions using standardised terminology, and structured reporting of disease status, treatment response categorisation, and any associated complications. KEY POINTS: MR Enterography and intestinal ultrasound are the key imaging modalities for the diagnosis and follow-up of luminal CD, with CT reserved primarily for the acute setting. Inflammation, or active disease, is the hallmark of luminal CD, and there are several validated mural and extramural imaging signs of activity, often coexisting with chronic changes. Changes in the imaging markers of active luminal CD are central to radiologists' judgement of treatment response and should be communicated in a standardised report in addition to any stricturing or penetrating complications.

Indexed as

Crohn DiseaseMagnetic Resonance ImagingEuropeHumansSocieties, MedicalTomography, X-Ray ComputedTreatment OutcomeUltrasonographyCrohn’s diseaseIntestine, Small bowelMagnetic resonance imagingUltrasound

Identifiers

PMID40500529
PMCPMC12634764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.